After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...
"Therapeutic innovations like elranatamab achieve a lasting response in 61% of patients with multiple myeloma and complete remission in 30%," said Dr María Victoria Mateos, a consultant physician in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results